Separate multivariable models according to PT-CY receipt
| . | No PT-CY . | PT-CY . | . | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | P (differential effect) . | |
| OS | |||||
| Age, per year | 1.00 (0.99-1.02) | .72 | 1.00 (.98-1.03) | .82 | .97 |
| RAEB-1 or −2 | 2.78 (1.11-6.96) | .028 | .81 (.33-2.00) | .65 | .060 |
| Transformation to AML | 3.69 (1.49-9.16) | .005 | 1.08 (.43-2.67) | .88 | .060 |
| Non-CR at transplant | 2.47 (1.44-4.25) | .001 | 1.32 (.70-2.49) | .39 | .14 |
| Bone marrow vs peripheral blood* | 1.17 (0.58-2.36) | .51 | .72 (.39-1.32) | .29 | .31 |
| Female donor to male recipient | 1.34 (0.78-2.28) | .29 | 2.02 (.97-4.21) | .059 | .37 |
| CM-positive recipient | 1.89 (1.04-3.45) | .038 | 1.19 (.49-2.86) | .70 | .39 |
| ≥2 HLA loci mismatch | 1.26 (0.68-2.31) | .46 | — | — | — |
| MAC | 1.52 (0.79-2.92) | .21 | 3.12 (1.21-8.04) | .018 | .22 |
| TBI | 0.90 (0.48-1.66) | .73 | 2.66 (.95-7.47) | .062 | .075 |
| In vivo TCD | 0.86 (0.45-1.65) | .60 | — | — | — |
| Ex-vivo TCD | 0.78 (0.31-1.96) | .60 | — | — | — |
| PFS | |||||
| Age, per year | 1.00 (0.99-1.02) | .76 | 1.01 (.99-1.04) | .29 | .51 |
| RAEB-1 or −2 | 2.58 (1.13-5.88) | .025 | .66 (.27-1.60) | .36 | .028 |
| Transformation to AML | 3.14 (1.38-7.15) | .007 | .87 (.36-2.14) | .77 | .040 |
| Non-CR at transplant | 2.31 (1.38-3.88) | .002 | 1.55 (.84-2.87) | .16 | .33 |
| Bone marrow vs peripheral blood* | 1.43 (0.73-2.78) | .30 | .91 (.50-1.63) | .74 | .32 |
| Female donor to male recipient | 1.22 (0.73-2.04) | .45 | 2.02 (1.00-4.08) | .050 | .26 |
| CMV-positive recipient | 1.62 (0.92-2.87) | .095 | 1.20 (.53-2.74) | .66 | .56 |
| ≥2 HLA loci mismatch | 1.28 (0.72-2.25) | .40 | — | — | — |
| MAC | 1.46 (0.76-2.80) | .25 | 2.71 (1.13-6.51) | .026 | .27 |
| TBI | 0.81 (0.45-1.44) | .47 | 2.58 (.99-6.69) | .052 | .041 |
| In vivo TCD | 0.87 (0.45-1.68) | .68 | — | — | — |
| Ex vivo TCD | 0.89 (0.37-2.15) | .79 | — | — | — |
| NRM | |||||
| Age, per year | 1.01 (0.99-1.03) | .47 | 1.02 (.99-1.05) | .31 | .68 |
| RAEB-1 or −2 | 1.72 (0.67-4.43) | .26 | .60 (.20-1.82) | .37 | .16 |
| Transformation to AML | 2.50 (0.98-6.35) | .055 | 1.00 (.33-2.98) | >.99 | .21 |
| Non-CR at transplant | 2.36 (1.28-4.35) | .006 | 1.16 (.54-2.50) | .70 | .16 |
| Bone marrow vs peripheral blood* | 0.86 (0.38-1.96) | .73 | .72 (.33-1.57) | .42 | .76 |
| Female donor to male recipient | 1.39 (0.77-2.51) | .28 | 2.27 (.95-5.39) | .064 | .36 |
| CMV-positive recipient | 1.96 (0.99-3.89) | .053 | 1.42 (.45-4.50) | .56 | .63 |
| ≥2 HLA loci mismatch | 1.24 (0.62-2.49) | .54 | — | — | — |
| MAC | 2.03 (0.95-4.36) | .068 | 2.01 (.75-5.39) | .16 | .99 |
| TBI | 0.99 (0.38-1.97) | .98 | 1.53 (.49-4.81) | .46 | .52 |
| In vivo TCD | 0.84 (0.41-1.75) | .74 | — | — | — |
| Ex vivo TCD | 0.58 (0.21-1.64) | .31 | — | — | — |
| . | No PT-CY . | PT-CY . | . | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | P (differential effect) . | |
| OS | |||||
| Age, per year | 1.00 (0.99-1.02) | .72 | 1.00 (.98-1.03) | .82 | .97 |
| RAEB-1 or −2 | 2.78 (1.11-6.96) | .028 | .81 (.33-2.00) | .65 | .060 |
| Transformation to AML | 3.69 (1.49-9.16) | .005 | 1.08 (.43-2.67) | .88 | .060 |
| Non-CR at transplant | 2.47 (1.44-4.25) | .001 | 1.32 (.70-2.49) | .39 | .14 |
| Bone marrow vs peripheral blood* | 1.17 (0.58-2.36) | .51 | .72 (.39-1.32) | .29 | .31 |
| Female donor to male recipient | 1.34 (0.78-2.28) | .29 | 2.02 (.97-4.21) | .059 | .37 |
| CM-positive recipient | 1.89 (1.04-3.45) | .038 | 1.19 (.49-2.86) | .70 | .39 |
| ≥2 HLA loci mismatch | 1.26 (0.68-2.31) | .46 | — | — | — |
| MAC | 1.52 (0.79-2.92) | .21 | 3.12 (1.21-8.04) | .018 | .22 |
| TBI | 0.90 (0.48-1.66) | .73 | 2.66 (.95-7.47) | .062 | .075 |
| In vivo TCD | 0.86 (0.45-1.65) | .60 | — | — | — |
| Ex-vivo TCD | 0.78 (0.31-1.96) | .60 | — | — | — |
| PFS | |||||
| Age, per year | 1.00 (0.99-1.02) | .76 | 1.01 (.99-1.04) | .29 | .51 |
| RAEB-1 or −2 | 2.58 (1.13-5.88) | .025 | .66 (.27-1.60) | .36 | .028 |
| Transformation to AML | 3.14 (1.38-7.15) | .007 | .87 (.36-2.14) | .77 | .040 |
| Non-CR at transplant | 2.31 (1.38-3.88) | .002 | 1.55 (.84-2.87) | .16 | .33 |
| Bone marrow vs peripheral blood* | 1.43 (0.73-2.78) | .30 | .91 (.50-1.63) | .74 | .32 |
| Female donor to male recipient | 1.22 (0.73-2.04) | .45 | 2.02 (1.00-4.08) | .050 | .26 |
| CMV-positive recipient | 1.62 (0.92-2.87) | .095 | 1.20 (.53-2.74) | .66 | .56 |
| ≥2 HLA loci mismatch | 1.28 (0.72-2.25) | .40 | — | — | — |
| MAC | 1.46 (0.76-2.80) | .25 | 2.71 (1.13-6.51) | .026 | .27 |
| TBI | 0.81 (0.45-1.44) | .47 | 2.58 (.99-6.69) | .052 | .041 |
| In vivo TCD | 0.87 (0.45-1.68) | .68 | — | — | — |
| Ex vivo TCD | 0.89 (0.37-2.15) | .79 | — | — | — |
| NRM | |||||
| Age, per year | 1.01 (0.99-1.03) | .47 | 1.02 (.99-1.05) | .31 | .68 |
| RAEB-1 or −2 | 1.72 (0.67-4.43) | .26 | .60 (.20-1.82) | .37 | .16 |
| Transformation to AML | 2.50 (0.98-6.35) | .055 | 1.00 (.33-2.98) | >.99 | .21 |
| Non-CR at transplant | 2.36 (1.28-4.35) | .006 | 1.16 (.54-2.50) | .70 | .16 |
| Bone marrow vs peripheral blood* | 0.86 (0.38-1.96) | .73 | .72 (.33-1.57) | .42 | .76 |
| Female donor to male recipient | 1.39 (0.77-2.51) | .28 | 2.27 (.95-5.39) | .064 | .36 |
| CMV-positive recipient | 1.96 (0.99-3.89) | .053 | 1.42 (.45-4.50) | .56 | .63 |
| ≥2 HLA loci mismatch | 1.24 (0.62-2.49) | .54 | — | — | — |
| MAC | 2.03 (0.95-4.36) | .068 | 2.01 (.75-5.39) | .16 | .99 |
| TBI | 0.99 (0.38-1.97) | .98 | 1.53 (.49-4.81) | .46 | .52 |
| In vivo TCD | 0.84 (0.41-1.75) | .74 | — | — | — |
| Ex vivo TCD | 0.58 (0.21-1.64) | .31 | — | — | — |
Results presented are pooled over imputed data sets.
—, number of patients were too few to perform statistical analysis.
*Comparison of bone marrow or peripheral blood as the source of stem cells, the reference is peripheral blood.